Food and Drug Administration
March 4, 2003
Factive® (gemifloxacin) Tablets
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Adverse Cutaneous Reactions to Drugs, Dr. Michael Bigby, MD, FDA (HTM) (PPT)Antimicrobial Resistance in Streptococcus Pnewmoniae - Inplications for Prescription Drug Labeling, Dr. John Powers, MD (HTM) (PPT)
Gemifloxacin - A Potent Dual Targeting Fluoroquinolone, Life Science (PDF)